Fox Run Management L.L.C. Invests $93,000 in Altimmune, Inc. (NASDAQ:ALT)

Fox Run Management L.L.C. bought a new stake in Altimmune, Inc. (NASDAQ:ALT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,905 shares of the company’s stock, valued at approximately $93,000.

Several other hedge funds have also bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of Altimmune during the 4th quarter valued at $81,000. American Century Companies Inc. raised its position in Altimmune by 35.8% during the fourth quarter. American Century Companies Inc. now owns 44,742 shares of the company’s stock valued at $323,000 after purchasing an additional 11,788 shares in the last quarter. Teacher Retirement System of Texas raised its position in Altimmune by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company’s stock valued at $153,000 after purchasing an additional 3,423 shares in the last quarter. Intech Investment Management LLC lifted its stake in Altimmune by 36.7% during the fourth quarter. Intech Investment Management LLC now owns 46,123 shares of the company’s stock worth $333,000 after purchasing an additional 12,385 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Altimmune by 34.5% in the 4th quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company’s stock worth $98,000 after purchasing an additional 3,500 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Stock Performance

Shares of ALT stock opened at $5.32 on Friday. Altimmune, Inc. has a fifty-two week low of $5.14 and a fifty-two week high of $11.16. The company has a market capitalization of $409.71 million, a P/E ratio of -3.43 and a beta of 0.87. The stock has a 50 day moving average price of $6.24 and a two-hundred day moving average price of $7.06.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. As a group, equities analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on ALT. Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research note on Tuesday, March 18th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Insider Buying and Selling

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.10% of the stock is owned by insiders.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.